SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization
SCIENTURE HOLDINGS (NASDAQ: SCNX) has announced two significant developments in its commercial operations. First, Michele Rath has been appointed as Senior Vice President and Chief Commercial Officer (CCO) of Scienture, , effective November 1, 2024. Rath brings over 20 years of industry experience from previous roles at Pfizer, CVS Caremark, and Aurobindo Pharma.
Second, the company has established a strategic partnership with Syneos Health Commercial Services through a Master Commercial Services Agreement (MCSA). Syneos Health will serve as Scienture's Contract Sales Organization, providing field sales, inside sales, and customer engagement services supported by their Kinetic platform analytics.
These developments aim to support the upcoming launches of two FDA-approved products: Arbli™ (losartan potassium) oral suspension and Rezenopy® (naloxone HCl) nasal spray.
SCIENTURE HOLDINGS (NASDAQ: SCNX) ha annunciato due sviluppi significativi nelle sue operazioni commerciali. In primo luogo, Michele Rath è stata nominata Vicepresidente Senior e Chief Commercial Officer (CCO) di Scienture, con effetto dal 1° novembre 2024. Rath porta con sé oltre 20 anni di esperienza nel settore, avendo ricoperto ruoli precedenti presso Pfizer, CVS Caremark e Aurobindo Pharma.
In secondo luogo, l'azienda ha stabilito una partnership strategica con Syneos Health Commercial Services tramite un Master Commercial Services Agreement (MCSA). Syneos Health fungerà da Organizzazione di Vendita Contrattuale per Scienture, fornendo servizi di vendita sul campo, vendite interne e servizi di coinvolgimento dei clienti supportati dalle loro analisi della piattaforma Kinetic.
Questi sviluppi mirano a supportare i prossimi lanci di due prodotti approvati dalla FDA: Arbli™ (sospensione orale di losartan potassico) e Rezenopy® (spray nasale di naloxone HCl).
SCIENTURE HOLDINGS (NASDAQ: SCNX) ha anunciado dos desarrollos significativos en sus operaciones comerciales. Primero, Michele Rath ha sido nombrada Vicepresidenta Senior y Directora Comercial (CCO) de Scienture, con efecto a partir del 1 de noviembre de 2024. Rath aporta más de 20 años de experiencia en la industria de roles previos en Pfizer, CVS Caremark y Aurobindo Pharma.
En segundo lugar, la compañía ha establecido una asociación estratégica con Syneos Health Commercial Services a través de un Master Commercial Services Agreement (MCSA). Syneos Health actuará como la Organización de Ventas por Contrato de Scienture, proporcionando servicios de ventas en campo, ventas internas y servicios de participación del cliente respaldados por sus análisis de la plataforma Kinetic.
Estos desarrollos tienen como objetivo apoyar los próximos lanzamientos de dos productos aprobados por la FDA: Arbli™ (suspensión oral de losartán potásico) y Rezenopy® (spray nasal de naloxona HCl).
SCIENTURE HOLDINGS (NASDAQ: SCNX)는 상업 운영에서 두 가지 중요한 발전을 발표했습니다. 첫째, Michele Rath가 2024년 11월 1일부터 Scienture의 수석 부사장 겸 최고 상업 책임자(CCO)로 임명되었습니다. Rath는 Pfizer, CVS Caremark 및 Aurobindo Pharma에서의 이전 역할을 통해 20년 이상의 산업 경험을 가지고 있습니다.
둘째, 회사는 Syneos Health Commercial Services와 마스터 상업 서비스 계약(MCSA)을 통해 전략적 파트너십을 체결했습니다. Syneos Health는 Scienture의 계약 판매 조직으로서 현장 판매, 내부 판매 및 고객 참여 서비스를 제공하며, Kinetic 플랫폼 분석으로 지원합니다.
이러한 발전은 FDA 승인을 받은 두 가지 제품의 출시를 지원하는 것을 목표로 합니다: Arbli™ (로사르탄 칼륨) 경구 현탁액 및 Rezenopy® (날록손 HCl) 비강 스프레이.
SCIENTURE HOLDINGS (NASDAQ: SCNX) a annoncé deux développements significatifs dans ses opérations commerciales. Tout d'abord, Michele Rath a été nommée Vice-Présidente Senior et Directrice Commerciale (CCO) de Scienture, à compter du 1er novembre 2024. Rath apporte plus de 20 ans d'expérience dans l'industrie, ayant occupé des postes précédents chez Pfizer, CVS Caremark et Aurobindo Pharma.
Deuxièmement, l'entreprise a établi un partenariat stratégique avec Syneos Health Commercial Services par le biais d'un Master Commercial Services Agreement (MCSA). Syneos Health agira en tant qu'Organisation de Vente Contractuelle pour Scienture, fournissant des services de vente sur le terrain, de vente interne et d'engagement client, soutenus par les analyses de leur plateforme Kinetic.
Ces développements visent à soutenir les prochains lancements de deux produits approuvés par la FDA : Arbli™ (suspension orale de losartan potassium) et Rezenopy® (spray nasal de naloxone HCl).
SCIENTURE HOLDINGS (NASDAQ: SCNX) hat zwei bedeutende Entwicklungen in seinen Geschäftstätigkeiten bekannt gegeben. Erstens wurde Michele Rath mit Wirkung zum 1. November 2024 zur Senior Vice President und Chief Commercial Officer (CCO) von Scienture ernannt. Rath bringt über 20 Jahre Branchenerfahrung aus früheren Positionen bei Pfizer, CVS Caremark und Aurobindo Pharma mit.
Zweitens hat das Unternehmen eine strategische Partnerschaft mit Syneos Health Commercial Services durch einen Master Commercial Services Agreement (MCSA) etabliert. Syneos Health wird als Vertragsvertriebsorganisation von Scienture fungieren und Außendienst, Innendienst und Kundenengagement-Dienstleistungen anbieten, die durch ihre Kinetic-Plattformanalysen unterstützt werden.
Diese Entwicklungen zielen darauf ab, die bevorstehenden Markteinführungen von zwei von der FDA genehmigten Produkten zu unterstützen: Arbli™ (Losartan-Kalium) orale Suspension und Rezenopy® (Naloxon HCl) Nasenspray.
- Strategic partnership with Syneos Health enhances commercial capabilities and market reach
- Two FDA-approved products ready for launch
- Appointment of experienced CCO with 20+ years industry background
- None.
Insights
Scienture's strategic agreement with Syneos Health represents a significant infrastructure development as the company transitions from product development to commercialization. By engaging Syneos as their Contract Sales Organization, Scienture gains access to an established commercial framework without incurring the substantial capital expenditure typically required to build an internal sales force from scratch.
The company is preparing to launch two FDA-approved products - Arbli (losartan potassium) oral suspension and Rezenopy (naloxone HCl) nasal spray. Both target established markets with standardized reimbursement pathways, potentially enabling more predictable revenue generation compared to novel therapeutics. The oral suspension formulation of losartan suggests a focus on differentiated delivery methods for existing molecules, which typically face fewer regulatory hurdles but must demonstrate unique value propositions in competitive markets.
Michele Rath's appointment as CCO brings valuable commercial leadership experience from major industry players including Pfizer and CVS Caremark. This executive addition coupled with the Syneos partnership indicates Scienture is assembling the necessary commercial infrastructure and expertise to execute their go-to-market strategy.
However, the announcement lacks critical details about implementation timeline, sales force sizing, and financial terms of the Syneos arrangement. Without these elements, it's difficult to project the partnership's immediate impact on the company's cash burn rate or potential revenue trajectory.
Scienture's decision to partner with Syneos Health represents a strategic approach to commercialization that balances capability building with financial flexibility. By leveraging Syneos' established infrastructure through their Master Commercial Services Agreement, Scienture can deploy a specialized sales organization without the fixed overhead costs of an internal team.
The partnership provides Scienture access to Syneos' Kinetic platform, which integrates predictive analytics with commercial operations. This technology-enabled approach can optimize sales force effectiveness through data-driven targeting and engagement strategies - particularly valuable for a company launching its first commercial products.
For a company with Scienture's
The agreement encompasses comprehensive commercial services including field and inside sales teams, suggesting a multi-channel approach to product promotion. This flexibility allows Scienture to scale commercial operations based on initial market response without committing to fixed infrastructure costs.
While the partnership demonstrates progress toward commercialization readiness, investors should note the announcement lacks specifics regarding implementation timelines, territories, or performance metrics. These details would be necessary to fully evaluate the potential revenue impact or required financial investment in the partnership.
TAMPA, FL, March 25, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce Michele Rath as Senior Vice President and Chief Commercial Officer (CCO) of Scienture, LLC, a wholly owned subsidiary of the Company, leading and managing Scienture, LLC’s commercial operations. Under Ms. Rath’s leadership, Scienture, LLC has formalized a strategic relationship with Syneos Health Commercial Services, LLC (“Syneos Health”), a premier biopharmaceutical solutions organization, by executing a Master Commercial Services Agreement with Syneos Health (the “MCSA”). Pursuant to the MCSA, Syneos Health will serve as Scienture, LLC’s Contract Sales Organization (CSO). This collaboration is set to enhance Scienture, LLC’s commercial capabilities and expand its market reach through Syneos Health’s proven expertise in outsourced sales solutions.
Ms. Rath, who joined Scienture in a full time capacity on November 1, 2024, brings over 20 years of industry experience, having previously served in key leadership roles at Pfizer, CVS Caremark and Aurobindo Pharma. With a proven track record in driving sales strategy, strategic marketing, sales operations and market access, she will spearhead Scienture, LLC’s commercial initiatives, focusing on revenue growth, strategic partnerships, and customer engagement.
Additionally, Scienture, LLC will leverage Syneos Health’s comprehensive suite of commercial services to drive greater awareness of Scienture, LLC’s products. This includes field sales, inside sales, and customer and tech-enabled engagement strategies. All will be unperpinned by the predictive and adaptive analytics capabilities of Syneos Health’s Kinetic platform designed to connect, harmonize and streamline end-to-end commercial solutions.
“We are thrilled to have Michele as part of our leadership team,” said Narasimhan Mani, Ph.D., MBA, President of Scienture, LLC. “Her deep expertise in commercial operations will be instrumental in the upcoming launches of our two FDA-approved brand products ArbliTM (losartan potassium) oral suspension and Rezenopy® (naloxone HCl) nasal spray. In addition, by leveraging Syneos Health’s expansive network and an innovative sales model, Scienture, LLC is well-positioned to accelerate our growth and better serve our customers.”
“We are very pleased to have Michele Rath as our CCO. She is a great addition to our executive team,” added Shankar Hariharan, Ph.D., CEO of Scienture, LLC. “Establishing a relationship with Syneos Health is a pivotal step in strengthening our commercial presence and optimizing our go-to-market strategy. By combining our innovative offerings with Syneos’ specialized sales expertise, we will be well-positioned to maximize our market potential.”
“We are excited to collaborate with Scienture to enhance its commercial effectiveness,” said Paul Mignon, President, Deployment Solutions, Syneos Health. “Our team is committed to delivering tailored sales strategies and deep industry insights to support Scienture in achieving its strategic vision and business goals.”
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiaries, Scienture, LLC and Integra Pharma Solutions, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Integra Pharma Solutions, LLC, is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to healthcare markets including government organizations, hospitals, clinics and independent pharmacies nationwide. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture, LLC are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit www.scienture.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch and the success those products may have in the marketplace. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
SCIENTURE HOLDINGS, INC.
6308 Benjamin Rd, Suite 708
Tampa, Florida 33634
Phone: (866) 468-6535
Email: IR@Scienture.com
FAQ
What products is SCNX planning to launch through the Syneos Health partnership?
When did Michele Rath join SCNX as Chief Commercial Officer?
What services will Syneos Health provide to SCNX under the MCSA agreement?
What is Michele Rath's professional background before joining SCNX?
